MEDICALLY REVIEWED

Teplizumab: Monoclonal Antibody Treatment for T1DM that was recently approved by FDA

Teplizumab is a CD3-directed monoclonal antibody (mAb) that is a genetically modified derivative of the CD3-directed murine OKT3 mAb.

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: